The purpose of this study is to demonstrate in patients with Parkinson's disease that, when
compared to levodopa/carbidopa, Stalevo will delay the time from initiation of study drug to
the time an increase in antiparkinsonian medication is required due to inadequately
controlled parkinsonian symptoms.